Table 2 Importance of unknown information during pre-screening for the four clinical trials of interest: importance of unknown information during pre-screening for the four clinical trials of interest
From: OWL model of clinical trial eligibility criteria compatible with partially-known information
CT1 | CT2 | CT3 | CT4 | |
|---|---|---|---|---|
Nb inclusion fields | 15 | 19 | 16 | 10 |
Nb exclusion fields | 10 | 9 | 8 | 11 |
Nb common fields | 3 | 0 | 2 | 3 |
Missing values | 50.06% | 61.72% | 56.52% | 42.99% |
Nb patients with all inclusion fields known | 0 | 0 | 1 | 1 |
Nb patients with all exclusion fields known | 4 | 3 | 0 | 1 |
Nb patients with all fields known | 0 | 0 | 0 | 0 |
Nb eligible patients | 30 | 23 | 6 | 2 |